
Software Engineer Intern - 2027
San Mateo, CA at a glance
- Rent
- #2 of 51$2,910/mo+46% vs US avg
- Weather
- #17 of 51298 mild days0 hot · 0 cold
- Income tax
- #1 of 5113.3% top rateCalifornia
What you need
- Strong software engineering, code quality focus
- First-principles reasoning, deep thinking
- Interest in biochemistry and drug development
What you'll do
- Build molecular/protein visualization and ML analysis tools
- Collaborate with ML engineers and chemists on computational methods
- Scale infrastructure for billions of datapoints and parallel DL jobs
Genesis Molecular AI is building a world-class software team to solve problems in drug discovery through machine learning, biophysical simulation, and computational chemistry. We are looking for engineers excited to help develop new medicines and play a critical role in building out our software platform.
You will
Build and expand on tools for visualizing molecules and proteins, analyzing machine learning models, and managing complex chemical workflows
Work closely with machine learning engineers and medicinal chemists to develop and productionize new computational methods for molecular property prediction
Help scale our core infrastructure to handle billions of datapoints and thousands of parallel deep learning and molecular dynamics jobs
You are
A strong software engineer who will write code quickly and uphold our code quality standards
A deep thinker who reasons from first principles over pattern matching
Interested in learning about biochemistry and the drug development process
What we offer
The opportunity to work on high impact tools and products that are immediately deployed to accelerate the discovery of new medicines
Strong technical coworkers in AI, software, and chemistry, who all have a powerful mix of intellectual curiosity and humility. The team reads and discusses 1-2 machine learning or chemistry papers every week to stay on top of the field and inspire new ideas
Application & Hiring Timeline
Application Deadline:
Resume Review:
Interviews Kick-Off:
About Genesis Molecular AI
Genesis Molecular AI is pioneering foundation models for molecular AI to unlock a new era of drug design and development. Our generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures. Genesis has also signed category-leading AI-pharma deals, the most recent of which was a significant expansion with Incyte (see coverage in Forbes and GEN) with a total potential deal value of several billion dollars.
Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
Optimize your resume for this job
Get a match score and the keywords you're missing
About Genesis Molecular AI
Genesis Molecular AI – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and offices in New York – is pioneering foundation models for molecular AI to unlock a new era of drug design and development. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI platform collaborations across a range of therapeutic areas including Gilead (2024), and Incyte (2025). Genesis has raised over $300M in funding from top AI, technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. To learn more about Genesis Molecular AI, or current employment opportunities, please visit our website.
Similar Software roles


